Who
James T. Parsons
Director
Company insider
Files Form 4 as: Director, Oncolytics Biotech; Director, DiaMedica Therapeutics; Chief Financial Officer, Trillium Therapeutics.
In numbers
- Trades disclosed
- 35
- Buys
- 2
- Sells
- 1
- Bought
- $30K
- Sold
- $134K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 11 Dec 2018
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,189 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,189 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $10K10,000 at $1.03 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $10K10,000 at $1.03 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $85K10,095 at $8.42 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $85K10,095 at $8.42 | filing |
| 21 Nov 2025filed 25 Nov 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code M | $26K12,000 at $2.20 | filing |
| 1 Jun 2025filed 3 Jun 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,739 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,287 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $85K15,917 at $5.34 | filing |
| 1 Jun 2024filed 3 Jun 2024 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,472 at $0.00 | filing |
| 2 Jan 2024filed 2 Jan 2024 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $60K21,428 at $2.80 | filing |
| 1 Jun 2023filed 2 Jun 2023 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,968 at $0.00 | filing |
| 1 Jun 2022filed 2 Jun 2022 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,222 at $0.00 | filing |
| 3 Jan 2022filed 3 Jan 2022 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | $60K16,773 at $3.58 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —180,000 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —94,792 at $0.00 | filing |
News
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 9.8% – Still a Buy?ONCY · dailypolitical.com · 16 Oct 2026Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentONCY · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name James T. Parsons; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.